Opioid overdose is now the leading cause of unintentional injury and death in the United States. But even as the term epidemic has been used in increasing frequency to characterize the problem, as of 2015, only 2.2% of US physicians had obtained waivers to prescribe buprenorphine.1 Perhaps it is no small irony that the clinicians who are most needed to understand and address this national crisis are among the least equipped: pediatricians, who represent just 0.8% of clinicians able to prescribe buprenorphine.1 Addressing this gap in care should be a priority for residency programs, the trainees of which will almost certainly contend with this issue. Given the severity of the opioid crisis nationally, all pediatric residency programs should offer buprenorphine training.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Dwarakanath M. The Case for Mandating Buprenorphine Training for Pediatric Resident Physicians. JAMA Pediatr. 2019;173(11):1013–1014. doi:https://doi.org/10.1001/jamapediatrics.2019.3208
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: